The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2

OBJECTIVES: On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ritonavir) as a treatment method that could reduce the risk of hospitalization or death for patients with confirmed coronavirus disease 2019 (COVID-19). METHODS: From February 6, 2022 to April 2, 2022, the incidence of COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hanul, Park, Young Joon, Lee, Hye Young, Yu, Mi, Song, Yeong-Jun, Lee, Sang Eun, Lee, Ji-Joo, Lee, Eun-Sol, Kim, Yeonjung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korea Disease Control and Prevention Agency 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10211435/
https://www.ncbi.nlm.nih.gov/pubmed/36617550
http://dx.doi.org/10.24171/j.phrp.2022.0262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10211435/
https://www.ncbi.nlm.nih.gov/pubmed/36617550
http://dx.doi.org/10.24171/j.phrp.2022.0262

Ejemplares similares